The life sciences and biotech community has endured a difficult few years. In Washington, the dismantling of federal agencies through job reductions, proposed spending cuts, declining grant funding, caps on indirect cost reimbursement, suspension of training programs, and turmoil at the FDA has created existential uncertainty about the US scientific establishment and its ability to maintain its globally dominant position as a technology leader.
At the same time continuing challenges on Wall Street have made investment in new life sciences companies challenging. In locations outside of Boston and the Bay Area, a lack of financing[JS1] and advisory services for early, pre-seed startups often fail to provide a clear path to the next tranche of investors who can provide the requisite seed and series A financing to enable sustainable venture creation. At the same time, venture capital is de-prioritizing early-stage ventures and rerouting funds to existing portfolio companies running out of cash as they face a lack of exits. Until very recently, the public markets have been closed to new offerings[JS2] .
These headwinds, from Washington to Wall Street, have stalled the early-stage research needed for true breakthroughs, leaving many brilliant ideas and discoveries stranded without money to generate the bridging data needed to advance them to investment readiness. This hasn’t gone unnoticed by our international competitors. Today, China-based programs nearly contribute as much to the global drug-discovery pipeline as the US[JS3] , with Europe now a distant third.
The good news is that life science innovation continues despite the challenges. Indeed, 2025 delivered some of the most influential science stories of the decade. To name a few: Cutting-edge CRISPR gene and base editing technologies are revolutionizing the landscape of drug discovery and rare disease treatment. AI is bolstering drug repurposing research, facilitating computer-aided drug design, and reducing attrition rates for drugs entering phase 1 human testing. Advances in materials science technologies offer fresh ways to address key challenges in reducing greenhouse gas emissions.
Sustaining this progress depends not just on good ideas but on the systems that nurture these ideas and help them to spread. And the systems of private and public funding for life sciences have been under duress for some time and remain in a period of great uncertainty.
As we look forward to continued scientific breakthroughs fueling new therapies, tools and products that will improve human health and accelerate progress towards a more sustainable and equitable future, we must look to new ways of working that can nurture and galvanize discovery and rebuild the capacity to get things done. Alternative financing mechanisms must be mobilized to stimulate impact investing and provide the long-term patient capital to fund research the market is currently ignoring.
Opportunity
We are living through a Fourth Industrial Revolution marked by rapid technological change and the convergence of physical, digital, and biological systems. Advances in the life sciences have the potential to transform human health, strengthen economic resilience, and create a more sustainable future.
The Challenge
Yet at the very moment when scientific innovation is accelerating, early-stage life science research faces a growing funding crisis.
Federal funding pressures, shifting investment priorities, and increasingly risk-averse capital markets have created a widening gap between discovery and commercialization. Transformational ideas emerging from universities, research institutions, and startups often lack the resources needed to generate the proof-of-concept data required to attract venture investment. As a result, promising breakthroughs remain stranded, weakening America’s long-term competitiveness and innovation pipeline.
A New Source of Capital
This challenge coincides with a historic rise in private wealth and philanthropic capital. Over the past five years, the number of single-family offices has grown by more than 30% to over 8,000 worldwide and is projected to exceed 10,000 by 2030, stewarding an estimated $9.5 trillion in assets. Alongside foundations, venture philanthropists, patient advocates, and mission-driven investors, these institutions represent an unprecedented source of long-term capital.
However, many family office/ philanthropic investors lack the expertise, networks, and infrastructure needed to confidently support early-stage life science research, where scientific complexity and development risk remain significant barriers.
The Solution: Connector Hubs
Connector Hubs is a new initiative designed to bridge this gap by building regional ecosystems that connect capital, talent, science, and industry around breakthrough discoveries.
The initiative mobilizes four forms of capital:
- Financial – Family offices, philanthropic foundations, patient communities, and mission-aligned investors.
- Scientific – Researchers, universities, academic medical centers, and scientific innovators.
- Human – Entrepreneurs, venture studios, translational experts, and startup leaders.
- Industry – Biotechnology companies, strategic partners, and commercialization pathways.
By aligning these resources within collaborative regional networks, Connector Hubs helps identify promising discoveries, accelerate translational research, launch sustainable startups, and unlock new pathways for impact investment.
Result
Connector Hubs creates a new model for advancing life science innovation, one that channels private capital toward breakthrough research, strengthens regional innovation. This accelerates the translation of discovery into impact, and helps rebuild U.S. leadership across science, technology, and biotechnology. The result is a more resilient, and effective innovation ecosystem capable of turning today’s scientific discoveries into tomorrow’s solutions.
For More Information, Contact:
info@nancyjkelley.com
Attention: Connector Hubs
[JS1] Including debt financing
[JS2] While M&A deal volume between pharma and biotech is down slightly 2024 vs 2023, deal VALUE Is down significantly.
[JS3] And this is increasingly novel innovations from China, beyond follow-on products and generics. China is also expediting its regulatory pathways to reduce time to market.